The DOI matches its Crossref record.
Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
Open accessAbstract
Purpose: High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. Patients and Methods: Patients with histologically confirmed, relapsed HL were treated with two cycles of dexamethasone, cytarabine, and cisplatin, and those without disease progression were randomly assigned. In the standard arm (A), patients received myeloablative therapy with carmustine, BEAM (carmustine, etoposide, cytarabine, and melphalan) followed by PBSCT. Patients in the experimental arm (B) also received sequential cyclophosphamide, methotrexate, and etoposide in high-doses before BEAM. Freedom from treatment failure (FFTF) was the primary end point. Remission rates, overall survival (OS), and toxicity of treatment were secondary end points. Results: From a total of 284 patients included, 241 responding patients were randomly assigned after two cycles of dexamethasone, cytarabine, and cisplatinum. Patients treated in arm B had longer treatment duration and experienced more toxicity and protocol violations (P < .05). Mortality was similar in both arms (20% and 18%). With a median observation time of 42 months, there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms. FFTF at 3 years was 62% (95% CI, 56% to 68%) and OS was 80% (95% CI, 75% to 85%). Patients with stage IV, early relapse, multiple relapse, anemia, or B symptoms had a higher risk of recurrence (P < .001). Conclusion: Compared with conventional high-dose chemotherapy, additional SHDCT is associated with more adverse effects and does not improve the prognosis of patients with relapsed HL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60165-9 · Cited by 742
Self-citationRothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Self-citationvon Tresckow, B., Plütschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M. S., Meissner, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5807 · Cited by 314
Self-citationYusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
“These have been the focus of phase III clinical trials in patients with relapsed hodgkin's lymphoma (NCT00025636) [135, 136], and men with previously untreated germ cell cancer (NCT00003941) [137].”
Metadata
- Authors
- Josting, A., Müller, H., Borchmann, P., Baars, J. W., Metzner, B., Döhner, H., Aurer, I., Smardova, L., Fischer, T., Niederwieser, D., Schäfer-Eckart, K., Schmitz, N., Sureda, A., Glossmann, J., Diehl, V., DeJong, D., Hansmann, M.-L., Raemaekers, J., & Engert, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-12-01
- Volume
- 28
- Issue
- 34
- Pages
- 5074-5080
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160483964
- Cited by
- 163
- References
- 0
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2010.30.5771
- The paper
- Josting, A., Müller, H., Borchmann, P., Baars, J. W., Metzner, B., Döhner, H., Aurer, I., Smardova, L., Fischer, T., Niederwieser, D., Schäfer-Eckart, K., Schmitz, N., Sureda, A., Glossmann, J., Diehl, V., DeJong, D., Hansmann, M.-L., Raemaekers, J., & Engert, A. (2010). Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.30.5771
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.